A Phase IIa, Randomised, Multi-centre, Double-blind, Placebo and Active-controlled, 3 Periods, Crossover Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Inhaled AZD8871 Administered Once Daily for 2 Weeks in Patients With Moderate to Severe COPD
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2018
At a glance
- Drugs AZD 8871 (Primary) ; Umeclidinium/vilanterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 07 Nov 2018 Planned End Date changed from 26 Sep 2019 to 23 Sep 2019.
- 07 Nov 2018 Planned primary completion date changed from 26 Sep 2019 to 23 Sep 2019.
- 07 Nov 2018 Status changed from not yet recruiting to recruiting.